Last reviewed: November 2017
Last updated: November  2017

Summary

Definition

History and exam

Key diagnostic factors

  • pain (anterior uveitis)
  • decreased vision
  • synechiae
  • flare
  • keratic precipitates

Other diagnostic factors

  • tearing
  • photophobia
  • floaters
  • eye redness without discharge
  • constricted or nonreactive pupil
  • decreased intraocular pressure
  • retinal exudates and edema, optic nerve edema
  • retinal vascular sheathing
  • macular edema
  • optic disk swelling
  • retinal hemorrhages
  • ciliary flush
  • corneal edema
  • cataract

Risk factors

  • inflammatory diseases of the joints, bowel, or skin
  • HLA-B27 positive
  • ocular trauma
  • age 30 to 40 years

Diagnostic investigations

Investigations to consider

  • CBC
  • ESR
  • CRP
  • fluorescent treponemal antibody (FTA-ABS), venereal disease research laboratory (VDRL), and rapid plasma reagin (RPR)
  • serum ACE
  • antinuclear antibodies
  • HLA-B27
  • Lyme titer
  • purified protein derivative (PPD) skin test
  • cytoplasmic anti-neutrophil cytoplasmic antibodies (c-ANCA)
  • perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA)
  • C3 and C4
  • anti-double-stranded DNA antibody (anti-dsDNA)
  • rheumatoid factor
  • anti-cyclic citrullinated peptide (anti-CCP) antibodies
  • Bartonella henselae titer
  • toxoplasma serologic titer
  • other HLA antigens
  • biochemistry screen
  • CXR
Full details

Emerging tests

  • vitreous biopsy
Full details

Treatment algorithm

Contributors

Authors VIEW ALL

President

Connecticut Uveitis Foundation

Associate Clinical Professor

Yale University

New Haven

Eye Disease Consultants

Hartford

CT

Disclosures

JJH declares that he has no competing interests.

Uveitis and Retina Specialist

Medical Eye Center of New Hampshire

Manchester

NH

Disclosures

ME declares that he has no competing interests.

Dr John J. Huang and Dr Max Elia would like to gratefully acknowledge Dr Richard Gale, Dr Zsolt Varga, Dr Victor L. Perez, and Dr Carlos A. Medina, the previous contributors to this monograph. RG, ZV, VLP, and CAM declare that they have no competing interests.

Peer reviewers VIEW ALL

Assistant Professor

Ophthalmology

Mount Sinai Hospital

New York

NY

Disclosures

JA declares that she has no competing interests.

Director of Ophthalmology

Alfred Hospital

Melbourne

Australia

Disclosures

AJH has been reimbursed by Novartis, the manufacturer of Lucentis, for lecture fees. AJH's employer, the Alfred Hospital, has received research funding from Novartis, the manufacturer of Lucentis, and from Bayer, the manufacturer of Eylea.

Chairman

Department of Ophthalmology

The University of Texas Health Science Center at San Antonio

San Antonio

TX

Disclosures

DAJ declares that he has no competing interests.

Use of this content is subject to our disclaimer